Cerba HealthCare, premier medical diagnosis market leader in Italy, starts team integration process to sustainably meet the diagnostic tool needs of patients, physicians, and hospitals’ nationwide.

Cerba HealthCare, a reference player in the field of medical diagnosis, has completed the acquisition of Lifebrain in Italy following an exclusive agreement reached this summer with    the shareholder, European Laboratory Solutions S.a.r.l., a company indirectly held by Investindustrial VI L.P. 

Based in France, Cerba HealthCare has sound positions in Europe and Africa where it holds historical track record in routine and specialty clinical pathology. Cerba HealthCare also has global presence and expertise in clinical pathology for clinical trials, which enables the company to validate and improve the effectiveness of new treatments and vaccines.

Lifebrain is a leading industry player in Italy where it is recognized for its unparalleled experience in acquisitions and its strong geographical presence that includes a network of three hubs and close to 360 sites.

Cerba HealthCare Italia CEO Stefano Massaro commented: “This acquisition is a milestone in Cerba HealthCare’s growth strategy. It strengthens our unique positioning in Italy, where we now have an extensive presence in 17 of the country’s 20 regions. We are proud to rely on cutting edge technology but most importantly on our multi-talented teams to fully meet the need for the growing diagnostic expertise required to best serve patients, physicians, and hospitals. All teams are thrilled to start working together and I am honoured to lead them on this important journey to achieve our best potential together”.

Financed by a combination of equity and debt, the acquisition has met all the legal requirements, such as administrative notifications and regulatory approvals, particularly from the Italian authorities.

Advisors include BofA Securities, EY, Loyens&Loeff, Goodwin (French corporate), Latham&Watkins (Corporate and Financing), Orrick Herrington & Sutcliffe, Paul Hastings, Schönherr.